1. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46 (Suppl T1): 17–24.
2. Andriole VT. The quinolones: past, present and future. Clin Infect Dis 2005; 41 (Suppl 2): S113–9.
3. Van Bambeke F, Michot JM, Van Eldere et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11 (4): 256–80.
4. Naber KG Adam D. Chemotherapy aaegot PESf. Classification of fluoroquinolones. Chemotherapie Journal 1998; 7: 66–8.
5. Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility. resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52 (4): 616–22.
6. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1–55.
7. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.
8. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26 (6): 1138–80.
9. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336 (4): 243–50.
10. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58 (5): 377–82.
11. Welte T, Petermann W, Schurmann D et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41 (12): 1697–705.
12. Portier H, Brambilla C, Garre M et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24 (6): 367–76.
13. Ewig S, Hecker H, Suttorp N et al. Moxifloxacin monotherapy versus ss-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia J Infect 2011.
14. Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46 (10): 1499–509.
15. Anzueto A, Niederman MS, Pearle J et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42 (1): 73–81.
16. Garau J, Fritsch A, Arvis P et al. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. J Chemother 2010; 22 (4): 264–6.
17. Sachs AP, Koeter GH, Groenier KH et al. Changes in symptoms peak expiratory flow. and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50 (7): 758–63.
18. Bent S, Saint S, Vittinghoff E et al. Antibiotics in acute bronchitis: a meta-analysis Am J Med 1999; 107 (1): 62–7.
19. Saint S, Bent S, Vittinghoff E et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis JAMA 1995; 273 (12): 957–60.
20. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125 (3): 953–64.
21. Miravitlles M, Llor C, Molina J et al. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. Int J Chron Obstruct Pulmon Dis 2010; 5: 11–9.
22. Meguro M, Barley EA, Spencer S et al. Development and Validation of an Improved. COPD-Specific Version of the St George Respiratory Questionnaire. Chest 2007; 132 (2): 456–63.
23. Sethi S, Jones PW, Theron MS et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.
24. Burke T, Villanueva C, Mariano H Jr et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther 1999; 21 (10): 1664–77.
25. Siegert R, Gehanno P, Nikolaidis P et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000; 94 (4): 337–44.
26. Rakkar S, Roberts K, Towe BF et al. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001; 55 (5): 309–15.
27. Anon JB. Current management of acute bacterial rhinosinusitis and the role of moxifloxacin. Clin Infect Dis 2005; 41 (Suppl. 2): S167–176.
28. Pletz MW, van der Linden M, von Baum H et al. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2011; 301 (1): 53–7.
29. Garcia-Rey C, Martin-Herrero JE, Baquero F. Antibiotic consumption and generation of resistance in Streptococcus pneumoniae: the paradoxical impact of quinolones in a complex selective landscape. Clin Microbiol Infect 2006; 12 (Suppl. 3): 55–66.
30. WHO: Treatment of tuberculosis: guidelines. 4th ed. In. 2010.
31. WHO: Guidelines for the programmatic management of drug-resistant tuberculosis. In Geneva Switzerland. World Health Organization 2008.
32. Poissy J, Aubry A, Fernandez C et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010; 54 (11): 4765–71.
33. Djukic M, Bottcher T, Wellmer A et al. Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis Neurocrit Care 2005; 2 (3): 325–29.
34. Hameed N, Tunkel AR. Treatment of Drug-resistant Pneumococcal Meningitis. Curr Infect Dis Rep 2010; 12 (4): 274–81.
35. Sipahi OR, Turhan T,Pullukcu H et al. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrob Chemother 2008; 61 (3): 670–3.
36. Solomkin J, Zhao YP, Ma EL et al. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.
37. Heystek M, Ross JD. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
38. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
39. Papaparaskevas J, Pantazatou A, Katsandri A et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 2008; 62 (1): 137–41.
40. Sacco F, Spezzaferro M, Amitrano M et al. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Dig Liver Dis 2010; 42 (2): 110–14.
41. Guay DR. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag 2006; 2 (4): 417–34.
42. Waites KB, Crabb DM, Duffy LB. Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2008; 52 (10): 3776–8.
43. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.

С.В.Сидоренко 

Научно-исследовательский институт детских инфекций, Санкт-Петербург; 
Кафедра клинической фармакологии РГМУ, Москва